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Oropharyngeal candidiasis is the most common fungal infection in hospitalized patients
with acquired immune deficiency syndrome (AIDS). Its progression results in invasive
infections, which are a significant cause of morbidity and mortality. This study aimed to
quickly and accurately identify Candida spp. from oral mucosa of AIDS patients recruited
at Presidente Vargas Hospital, in São Luís city, Brazil and to evaluate the sensitivity
profile of these fungi to antifungals by using an automated system. Isolates were
collected from oropharyngeal mucosa of 52 hospitalized AIDS patients, under anti-viral
and antifungal therapies. Patients were included in research if they were HIV-positive,
above 18 years of age and after obtaining their written consent. CHROMagar R©Candida
and the automated ViteK-2 R©system were used to isolate and identify Candida spp.,
respectively. Antifungal susceptibility testing was performed using the ViteK-2 R©system,
complemented with the Etest R©, using the drugs amphotericin B, fluconazole, flucytosine,
and voriconazole. Oropharyngeal candidiasis had a high prevalence in these hospitalized
AIDS patients (83%), and the most prevalent species was Candida albicans (56%).
Antifungal susceptibility test showed that 64.7% of the Candida spp. were susceptible,
11.8% were dose-dependent sensitive, and 23.5% were resistant. All the Candida krusei
and Candida famata isolates and two of Candida glabrata were resistant to fluconazole.
Most of AIDS patients presented oropharyngeal candidiasis and C. albicans was the
most frequently isolated species. The results showed high variability in resistance among
isolated species and indicates the need to identify the Candida spp. involved in the
infection and the need to test antifungal susceptibility as a guide in drug therapy in
patients hospitalized with AIDS. This is the first relate about AIDS patients monitoring
in a public hospital in São Luís concerning the precise identification and establishing of
antifungal profile of Candida spp..
Keywords: HIV, AIDS, antifungals, Candida, oropharyngeal candidiasis
Frontiers in Microbiology | www.frontiersin.org 1 March 2017 | Volume 8 | Article 298
fmicb-08-00298 February 28, 2017 Time: 15:57 # 2
Terças et al. Antifungal Susceptibility of HIV-Positive Isolates
INTRODUCTION
In recent decades, the increasing incidence of fungal infections
has been linked to patients with congenital or acquired
immunodeficiency (Ortega et al., 2010; Junqueira et al., 2012;
Li et al., 2013). Candida albicans is the most frequently isolated
species in humans (Delgado et al., 2009; Hise et al., 2009;
Junqueira et al., 2012; Li et al., 2013). However, there has been
a significant increase in the prevalence of infections caused by
species of Candida other than C. albicans such as C. krusei,
C. tropicalis, C. glabrata, C. guilliermondii, and C. parapsilosis
(Sant’Ana et al., 2002; Li et al., 2013; Kaur et al., 2016).
Despite the high effectiveness of the current antiretroviral
therapies, HIV+ subjects have a higher prevalence of
oropharyngeal candidiasis (OPC) than individuals without
this disease, and its expression is a predictive marker for
increased immunosuppression (Erkose and Erturan, 2007). The
advancement of HIV infection can result in more frequent and
severe OPC episodes (Sharma et al., 2009). The severity of the
disease, associated with debilitating conditions of patients, causes
prolonged hospital stays and higher hospital costs, generating a
major public health problem (Back-Brito et al., 2009).
The progression of oral candidiasis is often faster and more
severe in patients with AIDS due to immunodeficiency and
the emergency of antifungal resistance among Candida species
isolates. Also, in fungal infection, the identification of Candida
spp. is essential since the pathogenicity profile and sensitivity
to a particular antifungal agent vary between different species
(Costa et al., 2009; Negri et al., 2009). Some authors also argue
that exposure to antifungal agents during candidiasis treatment
provided a positive selection pressure for non-albicans yeasts,
such as C. glabrata and C. krusei (Hunter et al., 1998; Martinez
et al., 2002), that are considered intrinsically less sensitive than
others species (Pfaller, 2012).
Therefore, this variability in the behavior of different Candida
spp. and the increasing number of clinical isolates resistant to
current antifungal therapies highlight the need for antifungal
susceptibility testing to monitor the antifungal resistance of these
microorganisms. This could guide the therapeutic choice and
the clinical treatment. In addition, an accurate identification
of strains isolated from infections in patients with AIDS is
important because these patients are more likely to carry species
other than C. albicans that may be less sensitive to antifungal
agents (Belazi et al., 2005; Li et al., 2013; Idelevich et al., 2014).
Antifungal agents available for the treatment of candidiasis
are as follows: the polyenes [nystatin and amphotericin B
(AMB)]; the ergosterol biosynthesis inhibitors – the azoles
(miconazole, clotrimazole, ketoconazole, itraconazole, and FCZ),
allylaminesthiocarbamates, and morpholines; and DNA analog 5-
fluorocytosine, and newer agents such as caspofungins (Pappas
et al., 2009). The antifungal agents target three cellular
components of fungi. Azoles inhibit the synthesis of ergosterol
in the endoplasmic reticulum of the fungal cell. Polyenes such
as AMB bind to ergosterol in the fungal membrane causing
disruption of membrane structure and function. Flucytosine (5-
FC) is converted within the fungal cell to 5-fluorouracil, which
inhibits DNA synthesis (Patil et al., 2015). All can be used with
varying efficacy depending on the type and site of infection and
the sensitivity of the Candida species (Pfaller et al., 2010). For
most Candida infections, FCZ is the drug of choice (Pfaller et al.,
2010; Patil et al., 2015).
Like many others cities in developing countries such as São
Luís in Brazil, antifungal testing is not performed routinely
(Hamza et al., 2008; Costa et al., 2009). Also, to the best of
our knowledge, there are no studies that have established the
prevalence or evaluated the profile of antifungal sensitivity of
clinical isolates obtained from AIDS patients in São Luís city,
Northeast Brazil. Importantly, the mortality rate for AIDS cases
in Maranhão in 2013 is the highest in the Northeast: 6.6 cases
per 100,000 inhabitants. In addition, a total of 249 new cases of
AIDS has been confirmed in São Luís in 2013 (Brazil, Ministério
da Saúde, 2014).
Thus, this study was conducted with the objective of
identifying Candida spp. from oropharynx in hospitalized AIDS
patients using the automated ViteK-2system. We also aimed
to evaluate and compare the sensitivity profile of these yeasts
to four antifungal drugs, FCZ, AMB, 5-FC, and voriconazole
(VCZ), using the ViteK-2 and Etest systems in order to guide the
therapeutic choice and the clinical treatment of these patients.
MATERIALS AND METHODS
Patients and Oral Isolates
The Candida spp. were obtained by swabbing the oropharyngeal
mucosa of 52 AIDS patients hospitalized in Getúlio Vargas
Hospital in São Luis, Brazil. Patients were included in research
if they were HIV-positive, above 18 years of age and submitted
their written consent (Ethics Committee of Federal University
of Maranhão process No. 23115006540/2009-40). Some patients
were under anti-viral and antifungal therapies. Among the
patients, there were 22 females and 30 males in the age range of
19–61 years.
The patients in this study presented CD4+ cell counts
ranging from 10 to 552 cells/mm3 and viral loads of 2,567 to
256,860 copies/mL. Sterile swabs were used for the collection
of samples and were inoculated into tubes containing saline
solution P.A 0.85% (ISOFAR, Paraná, Brazil). They were then
sent to the Medical Mycology Laboratory of Ceuma University
and were incubated in BHI (Broth Heart Infusion – Acumedia
Manufactures) at 37◦C for 48 h.
Candida spp. Identification and
Preparation of Inoculums
The primary isolation of yeasts was performed using the
CHROMagar R©Candida (Difco) Chromogenic differential
medium in Petri dishes and incubated at 37◦C for 48 h. This
medium is based on the use of β-glucosaminidase substrate and
differentiates yeast according to the morphology and the color of
the colonies. This method provides a presumptive diagnosis of
Candida spp. (Hospenthal et al., 2004). Green colored colonies
were identified as C. albicans, blue-cobalt as C. tropicalis, pink or
lilac as C. krusei, and other species were whitish-pink in color.
The isolated yeasts from chromogenic medium were picked
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and incubated at 35◦C for 48 h in tubes with SDA (Sabouraud
Dextrose Agar with chloramphenicol – Acumedia) medium and
then stored at−20◦C for use in the study.
The biochemical identification of the yeasts was performed
using an automated method (Vitek-2 Compact bioMérieux,
Marcy-l’Étoile, France).
The Biomerieux Vitek-2 system includes the Vitek-
2 cards that allow species identification by comparison
of the biochemical profile with an extensive database
http://www.jgid.org/article.asp?issn=0974-174777X;year=2016;
volume=8;issue=4;spage=139;epage=146;aulast=Kaur-ref9
(Cuenca-Estrella et al., 2010). Biomerieux Vitek-2 expanded
its role in this area with a yeast susceptibility test that
determines Candida growth spectrophotometrically using
Vitek-2 microbiology systems, performing fully automated
testing of susceptibility to 5-FC, AMB, FCZ, and VCZ (Borghi
et al., 2010).
For the preparation of the fungal inoculum (3 mL
0.45% saline + yeast colony), a McFarland scale 2
from DensiChek-bioMerieuxVitek R© system was used.
This standardized suspension was aspirated into the
identification cards, and then the cards were sealed
and subjected to biochemical tests by an optical sensor
reading. We used the YST card (Yeast identification,
bioMérieux) to determine the genus and species of yeast.
The test was considered complete when the percentage of
probability was ≥85% and there was no request for further
testing.
In vitro Antifungals Susceptibility Tests
Thereafter, antifungal susceptibility tests (AFST) were
conducted using the ViteK-2 R© automated system and Etest R©
(Biodisk AB, Solna, Sweden) according to the manufacturer’s
recommendations. These methods have been chosen because
they are easy to perform and offer results in a short period of
time (Kaur et al., 2016).
For this, 180 µL of inoculum was standardized to the
McFarland scale 2.0 using the DensiChek densitometer of the
ViteK-2 R© system, placed in a tube containing 3 mL of 0.45%
saline, and aspirated into the AST-YSO1 card (bioMérieux). The
following antifungal drugs were tested: AMB (0.03–16 µg/mL),
FCZ (1–64 µg/mL), 5-FC (0.125–64 µg/mL), and VCZ (0.125–
16 µg/ml). The analysis and interpretation of data were
performed according to M27-A3 and M27-S3 CLSI standards.
For quality control, we used standard strains of C. krusei (ATCC
6258) and C. parapsilosis (ATCC 22019). For fungal strains that
did not respond to the AST cards, an Etest R© (Biodisk AB, Solna,
Sweden) was performed, which consisted of a gradient method
with predefined concentrations of FCZ and AMB in µg/mL. In
this method, the colonies were seeded at a concentration of 0.5
McFarland on dishes with RPMI (Probac R©, Sao Paulo, Brazil)
supplemented with 2% glucose agar and then incubated at 35◦C
for 48 h. The reading was performed by assessing the point of
intersection between the halo formed and the Etest strip. The FCZ
MIC was determined as the lowest concentration that inhibited
80% of fungal strains, and the AMB MIC was calculated as the
lowest concentration with no observed fungal growth. The profile
of the antifungal drug sensitivity was classified as sensitive (S),
dose-dependent sensitivity (S-DD), and/or intermediate (I), and
resistant (R).
The breakpoints used to define sensitivity, intermediate,
and resistant for each species were those defined by Clinical
and Laboratory Standards Institute [CLSI] (2008). The MIC
values ≤ 8 µg/mL for FCZ were considered susceptible (S), 16–
32 µg/mL was considered as susceptible dose-dependent (SDD),
and ≥64 µg/mL as resistant (R). For AMB, MICs ≤ 1 µg/mL
were considered to be S and ≥1 µg/mL was R. For 5-FC,
CIMs ≤ 4 µg/mL were considered to be S, 8–16 µg/mL was I,
and ≥32 µg/mL was R. For VCZ, MICs ≤ 0,125 µg/mL were S
and ≥16 µg/mL were considered R.
Fluconazole and amphotericin were chosen for the tests
because they have different mechanisms of action and are the
main drugs chosen for the treatment of Candida infections (Patil
et al., 2015). VCZ and 5-FC were chosen because they could be an
alternative for species resistant to FCZ and amphotericin.
Ethics Statement
The study protocol was established according to the Guidelines
and Standards for Research Involving Humans (Resolution of
the National Council No. 196/96 of October 10, 1996) and was
approved by the Ethics Committee of UFMA (Federal University
of Maranhão) under decision No. 23115006540/2009-40. All the
participants signed a free and informed consent form.
Statistical Analysis
The data collected were expressed as mean and standard
deviation for numeric variables, and absolute and relative
frequencies for categorical variables. We used the chi-squared
(χ2) test to analyze categorical variables, and analysis of variance
(ANOVA) followed by the Tukey’s post-test was used for numeric
variables when p < 0.05. A significance level of p < 0.05 was
adopted.
RESULTS
Patient Data and Prevalence of Isolates
From 52 AIDS patients participating in the study, 43 were
positive for Candida. Fifty-four fungal isolates were recovered
from these patients, and thus, in some cases, more than one
species was isolated from a single clinical sample. Eighty-three
percent of patients participating in the study had oropharyngeal
candidiasis, and 52.2% had used antifungals. Of these, 75% were
using both FCZ and nystatin and 8.3% used FCZ, nystatin, and
AMB.
Among the yeast samples, 43 (83%) grew in CHROMagar
Candida medium and 9 (17%) were negative. Using the
automated Vitek-2 R© Compact bioMérieux system, 51 isolates
were identified as Candida spp., including 29 C. albicans (56%),
6 C. tropicalis (12%), 6 C. krusei (12%), 4 C. glabrata (8%), 2
C. famata (4%), 2 C. parapsilosis (4%), and 2 C. guilliermondii
(4%) (Table 1). One isolate of Kodamaeaohmeri (Pichia ohmeri),
one of Rhodotorula spp., and one of Trichosporon spp. were also
identified.
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TABLE 1 | Number and prevalence (%) of the Candida strains identified by
the Vitek-2 R© system, and their distribution according to patient gender.
Species N. Isolates Female Male
Candida albicans 29(56%) 11 18
Candida tropicalis 6 (12%) 3 3
Candida krusei 6(12%) 2 4
Candida glabrata 4 (8%) 2 2
Candida guilliermondii 2 (4%) 1 1
Candida parapsilosis 2 (4%) 1 1
Candida famata 2 (4%) 2 0
Total 51 22 (43%) 29 (57%)
Chi-squared test (χ2): there was no statistically significant difference in the
incidence of Candida spp. analyzed according to gender (p = 0.74).
When looking at the distribution of isolates of Candida spp. by
patients’ gender, we observed that the number of isolates coming
from the men patients (n = 29/57%) was higher than that from
the women (n= 22/43%; Table 1). The age group with the highest
frequency of Candida spp. isolates was 30–40 years (50.98%),
followed by the 20–29 years age group (27.45%; Figure 1).
In vitro Susceptibility of Isolates
The antifungal susceptibility testing performed by the automated
ViteK-2 R© system showed that 58% of tests were completed in
a period of 12–15 h, and most of them did not exceed 19 h.
However, for four slow-growing or nutritionally fastidious and
demanding microorganisms, 36 h was not sufficient to obtain the
results. These cases included the following isolates: 2 C. famata, 1
Rhodotorulaglutinis, 1 Trichosporon spp., and 1 Kodamaeaohmeri
(Pichia ohmeri). For these isolates, the MIC was determined using
the Etest R© system. The results showed that all strains of C. albicans
(n = 29), C. tropicalis (n = 6), C. parapsilosis (n = 2), and
C. guilliermondii (n = 2) showed sensitivity to all antifungals
drugs tested. All six isolates of C. krusei were resistant to FCZ,
four of them showed intermediate susceptibility to 5-FC, and
all were sensitive to AMB and VCZ (Table 2). Two C. glabrata
isolates were resistant to FCZ, one was resistant to AMB, and
another one was resistant to VCZ. The sensitivity profile of the
antifungals tested was virtually the same for all of the Candida
spp. used in the survey, except for C. krusei and C. famata, which
were resistant to FCZ. C. glabrata isolates showed resistance
to three different antifungals. However, this small difference
in sensitivity toward the antifungals in these three species
did not translate to a statistically significant difference. The
ANOVA test showed no difference in the sensitivity profile
(p = 0.99), S-DD (p = 0.51), and resistance (p = 0.18) of the
antifungals.
In the susceptibility test performed using the Etest R© method,
two isolates of C. famata were resistant to FCZ but were
susceptible to AMB. Rhodotorulaglutinis isolates were resistant
to FCZ and AMB. Trichosporon spp. isolates were susceptible to
FCZ and resistant to AMB. Kodamaeaohmeri (Pichia ohmeri) was
resistant to FCZ but it displayed sensitivity to AMB (Table 3).
DISCUSSION
Oropharyngeal candidiasis is the most common opportunistic
infection among HIV-seropositive patients and in those with
AIDS, and it represents a major treatment challenge. Hence, it is
recommended to determine the species involved in the infection
and its antifungal susceptibility.
Among 52 patients involved in this study, 30 were men and 22
were women, resulting in the ratio of 1.4 cases in men for every
1 case in women. These findings lead us to reflect on whether the
incidence of AIDS in women is increasing and equating with the
incidence in males. Data from the last epidemiological study in
Brazil, published in the AIDS and STDs Bulletin in 2011, showed
that in 2011, the ratio of 1.7 cases in men for every 1 case in
women was greatly diminished when compared to data from
1989, when there were about six cases of AIDS in men for every
case in women (Hinrichsen et al., 2008). In the present study, we
also found that the most prevalent age group was 30–39 years,
followed by the 40–49 years age group. These data are similar
to those published in Brazil (Hinrichsen et al., 2008) and other
countries (Hamza et al., 2008).
FIGURE 1 | Distribution (%) of hospitalized patients with acquired immune deficiency syndrome (AIDS) by age group (years).
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TABLE 2 | Distribution of isolates of Candida spp. according to the
minimum inhibitory concentration (MIC) against four antifungal drugs as
evaluated by the Vitek 2 R© system.
Species Candida spp. No. (%) Sensitivity Profile
Total (%) S (%) S-DD(I) (%) R (%)
C. albicans 29 (56)
Fluconazole 29 (100) 0 0
Amphotericin B 29 (100) 0 0
Voriconazole 29 (100) 0 0
Flucytosine 29 (100) 0 0
C. tropicalis 6 (12)
Fluconazole 6 (100) 0 0
Amphotericin B 6 (100) 0 0
Voriconazole 6 (100) 0 0
Flucytosine 6 (100) 0 0
C. glabrata 4 (8)
Fluconazole 2 (50) 0 2 (50)
Amphotericin B 3 (75) 0 1 (25)
Voriconazole 3 (75) 0 1 (25)
Flucytosine 4 (100) 0 0
C. krusei 6 (12)
Fluconazole 0 0 6 (100)
Amphotericin B 6 (100) 0 0
Voriconazole 6 (100) 0 0
Flucytosine 2 (33) 4(67) 0
C. guilliermondii 2 (4)
Fluconazole 2 (100) 0 0
Amphotericin B 2 (100) 0 0
Voriconazole 2 (100) 0 0
Flucytosine 2 (100) 0 0
C. parapsilosis 2 (4)
Fluconazole 2 (100) 0 0
Amphotericin B 2 (100) 0 0
Voriconazole 2 (100) 0 0
Flucytosine 2 (100) 0 0
Classification according to the rules of the Clinical and Laboratory Standards
Institute M27-A3: Fluconazole (S≤ 8 µg/mL; S-DD, 16–32 µg/mL; R≥ 64 µg/ml);
Voriconazole (S ≤ 1 µg/mL; SDD, 2 µg/mL; R ≥ 4 µg/mL); Flucytosine
(S ≤ 4 µg/mL; I, 8–16 µg/mL; R ≥ 32 µg/mL); Amphotericin B (S < 1 µg/mL;
R > 2 µg/mL). S, sensitive; S-DD, dose-dependent sensitivity; I, intermediate
sensitivity; R, resistant.
The patients hospitalized with AIDS in this study presented
a low CD4+ lymphocyte count (90% of patients had less
than 200 cells/mm3) and a high viral load (80% of patients
had above 50,000 copies/mL). Although 90% of patients had
CD4+ lymphocyte counts below 200 cells/mm3, studies have not
shown any correlation between oral candidiasis and low CD4+
lymphocyte counts, but they have shown correlation with a high
viral load (Morgan, 2005; Erkose and Erturan, 2007; Back-Brito
et al., 2009). This study also showed a high frequency of OPC in
these patients (83%), and most of them had exposure to more
than one antifungal agent, including FCZ, nystatin, and AMB.
These data are alarming and support the relevance of our research
since we isolated a very high frequency of resistant yeasts. As far
as we know, this is the first study with AIDS patients from the
TABLE 3 | Minimum inhibitory concentrations (MIC) as evaluated by the
Etest R©system of four different fungals.
Fungal species Fluconazole Amphotericin B
Candida famata 128 (R) 0.75 (S)
Kodamaeaohmeri >256 (R) 0.38 (S)
Rhodotorulaglutinis >256 (R) 2 (R)
Trichosporon spp. 3 (S) 32 (R)
Classification according to the rules of the Clinical and Laboratory Standards
Institute M27-A3: Fluconazole (S ≤ 8 µg/mL; S-DD, 16–32 µg/mL;
R ≥ 64 µg/mL); Amphotericin B (S < 1 µg/mL; R > 1 µg/mL). S, sensitive;
S-DD, dose-dependent sensitivity; R, resistant.
city of São Luís concerning the distribution of oral yeasts, species
prevalence, and antifungal susceptibility profile.
The isolation of Candida species in this study was performed
by the CHROMagar Candida culture medium, and consequently,
it presumptively identified some species involved. Thereafter, we
used the ViteK-2system, a system with excellent reproducibility
and accuracy when compared with the CLSI method (Clinical
and Laboratory Standards Institute [CLSI], 2008; Bourgeois
et al., 2010; Cuenca-Estrella et al., 2010; Kaur et al., 2016) for
identification of all isolates. Among the 52 patients admitted with
AIDS who submitted to buccal smears, 43 (83%) were positive for
Candida ssp. culture. This result is similar to that found in other
studies, which showed that 80–95% of these patients develop one
or more fungal infections during their illness (Rex et al., 2000;
Campisi et al., 2002, Junqueira et al., 2012). In this study, we
observed that C. albicans was the most prevalent species (56%)
against all non-albicans Candida species (NAC; 44%), which is
in accordance with other studies (Viudes et al., 2002; Colombo
et al., 2006; Kaur et al., 2016). Among the NAC species, the most
prevalent species were C. tropicalis, C. krusei, and C. glabrata,
which is in agreement with other studies (Colombo et al., 2006;
Hamza et al., 2008). In this study, we identified a case of a patient
with four Candida spp. that were identified in a single clinical
sample; one of the species was C. glabrata, which is resistant
to both FCZ and AMB, and the other was C. krusei, which is
resistant to FCZ. This finding is relevant because FCZ is the drug
of choice for candidiasis treatment in AIDS patients although
it has a fungistatic action (Siikala et al., 2010; Rautemaa and
Ramage, 2011), and both FCZ and AMB were being used by some
of the patients who participated in the research. Seven patients
had double colonization, and one of them had colonization by
C. krusei resistant to FCZ. The coexistence of various species in
the same clinical specimen has also been reported in other studies
(Swinne et al., 2004; Junqueira et al., 2012).
We used the automated ViteK-2 R© and Etest R© systems to
screen for AFST because they present good reproducibility
and rapid diagnostic tests with Candida spp. (Pfaller et al.,
2007; Borghi et al., 2010; Bourgeois et al., 2010; Cuenca-Estrella
et al., 2010; Kaur et al., 2016). Both methods have advantages
over the Clinical and Laboratory Standards Institute (CLSI)
standardized broth microdilution method, which is considered
as a reference for antifungal susceptibility testing although it is
complex and laborious to use as a routine method (Bourgeois
et al., 2010; Kaur et al., 2016). The VK2 method demonstrated
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excellent reproducibility, which underscores its excellent
level of standardization. Spectrophotometric readings remove
subjectivity from the MIC determination. Furthermore, Candida
species identification and in vitro antifungal susceptibility are
obtained in less than 26.5 h (mean, 15.2 h), thus, reducing the
time necessary for optimizing antifungal treatment decisions.
ViteK-2 R© system results are on average available within 15 h
13 min, with a range of 12 h 15 min (C. albicans) to 26 h 30 min
(C. glabrata; Bourgeois et al., 2010). The Etest R© method is an
alternative, standardized, and reliable method adapted to hospital
laboratories. This method provides an accurate MIC value, and
this critical information helps the clinician to ensure that the
appropriate treatment of the patient will be achieved (Pfaller
et al., 1998; Bourgeois et al., 2010).
Nevertheless, in this study, some fastidious species failed
to grow sufficiently when we used the automated ViteK-2 R©
system, but for the Etest R© method, all of the isolates grew
enough to be read at 24 and 48 h. Thus, we note that, when
used in conjunction with the ViteK-2 R© method, these two AST
methods have the potential to satisfy all the requirements for
susceptibility testing in routine clinical microbiology analysis.
Generally, many authors use one or another method, mainly the
classical, laborious, and time consuming microdilution method
described in the CLSI M27-A3 standard (Bremenkamp et al.,
2011; Melo et al., 2011; Li et al., 2013; Sanitá et al., 2013), which is
still considered the gold standard for susceptibility tests.
In this study, all isolates of C. albicans (n = 29), C. tropicalis
(n = 6), C. parapsilosis (n = 2), and C. guilliermondii (n = 2)
showed sensitivity to all of the antifungal drugs tested, which is
consistent with the general pattern of susceptibility of the NCLS
M-27 method and with the results of other studies (Pfaller et al.,
2007, 2008). Eighty percent of the Candida spp. studied were
sensitive to FCZ, 18% were resistant, and 2% presented a S-DD.
These results are similar to those observed by other researchers
(Hospenthal et al., 2004; Pfaller et al., 2007; Hamza et al., 2008).
Resistance to FCZ was observed in this study in all six samples of
C. krusei (100%), two of C. glabrata (50%), and all of C. famata
(100%). In fact, C. krusei has an innate resistance to FCZ, and
C. glabrata possesses the capacity to develop resistance after
the first contact with this antifungal agent. The results of this
study are in agreement with several studies that demonstrated the
innate resistance of C. krusei to FCZ and the increased resistance
of C. glabrata and C. famata species to this antifungal drug
(Campisi et al., 2002; Hamza et al., 2008; Pfaller et al., 2008;
Junqueira et al., 2012; Patil et al., 2015).
Regarding VCZ, almost all Candida spp. isolates in this study
were sensitive to this drug, and only C. glabrata demonstrated
resistance. Based on these data, VCZ could be an effective drug
for the treatment of patients involved in the study. In fact, studies
have shown that VCZ is effective against Candida spp. that were
resistant to FCZ and/or AMB (Swinne et al., 2004; Pfaller et al.,
2007).
For AMB, the cutoff point (breakpoints) had not been
determined by CLSI. Researchers have determined that a value
of <1 µg/mL for an isolated strain would show sensitivity to
AMB, and a value of >1 µg/mL would demonstrate resistance
(Hepburn et al., 2003; Kaur et al., 2016). According to these
cutoffs, this study showed that 94% of the Candida isolates
were sensitive, 2% presented S-DD, and 4% were resistant.
These results were similar to those from other studies, where
upon examination of 100 HIV-infected patients revealed 58
with positive cultures for Candida spp., and of these, 96% were
susceptible to AMB and 4% were resistant (Alves et al., 2006).
Despite 50 years of polyene use, resistance to AMB is rare because
it binds to ergosterol in the fungal membrane causing disruption
of membrane structure and function, having, thus, a fungicide
action (Patil et al., 2015). However, it is worth noting that among
the non-Candida yeasts isolated in this study, two were resistant
to AMB and two were resistant to FCZ. One of them was resistant
to both antifungals, which draws our attention to the danger of
treatment without the precise identification and establishment of
the antifungal profile.
With regard to 5-FC, a high sensitivity of Candida isolates
(92%) was observed in this study probably because this antifungal
inhibits DNA synthesis (Patil et al., 2015). Only four (8%)
C. krusei samples showed S-DD. Flucytosine has a high activity
against C. albicans, although it has been reported that 40% of
C. krusei strains are resistant to this drug. Flucytosine should be
used as a treatment option only when the Candida spp. is resistant
to the azole antifungal family (Alves et al., 2006).
Many public hospitals that treat patients with HIV/AIDS do
not have the laboratory facilities that allow a rapid and accurate
diagnosis for treatment planning. Our results showed that OPC
infection has a high prevalence in hospitalized AIDS patients
(83%), and although all C. albicans were sensitive to the drugs
tested, most of the NAC species showed high resistance to more
than one antifungal agents (30%). Most of the observed resistance
was to FCZ, and the species that highlights as resistant were
C. krusei (100%), C. famata (100%), and C. glabrata (50%).
Also, 25% of C. glabrata were resistant to AMB and 40% of
C. krusei were intermediate to 5-FC. These findings are important
because they show the variable resistance profile among different
strains and the need to identify the Candida spp. involved in
the infection, mainly because the patients involved were or had
been on antifungal treatment. This also demonstrates the use
of antifungal susceptibility testing as a guide to drug therapy in
hospitalized AIDS patients.
Determining the MIC of a drug does not guarantee the success
of the treatment because, in an infection, the role of the host
is critical to obtain a satisfactory clinical response. However, it
is known that when the profile of a Candida spp. is resistant at
a tested drug concentration, this concentration often leads to a
failed clinical treatment (Rex et al., 2000).
We found a high prevalence of OPC and high frequency of
resistant Candida spp. in AIDS patients in a public hospital
in Sao Luis. São Luís is a city in the northeast of Brazil with
the highest number of cases of AIDS, and like other cities in
developing countries, in vitro antifungal testing is not performed
routinely. Monitoring clinical samples is extremely important
for the selection of the appropriate drug and dose, which helps
predict those patients who are likely to respond to therapy
and ensure prevention of excessive dosing and selection of
resistant microorganisms. The data obtained here allowed the
most effective monitoring of these patients, providing them with
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the possibility of more adequate therapy. It is noteworthy that the
Vitek-2 R© automated system used in conjunction with the Etest R©
meets all the requirements for the susceptibility testing of fungi
in routine clinical microbiology laboratories.
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